Xenetic reports Q3 EPS (33c) vs. (28c) last year

Reports Q3 revenue $1M vs. $0.6M last year. “We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with established cancer therapies,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic (XBIO). “The partnerships we’ve formed continue to generate critical data that we believe will help us guide our development and regulatory strategies to fully realize the promise of our DNase technology. The underwritten public offering we completed in October 2025 extends our cash runway and provides us additional capital to continue to invest in pre-clinical efforts and exploratory studies and advance our technology toward an IND submission and Phase 1 initiation.”